Dose-escalation study of proton beam therapy with chemotherapy for locally advanced non-small lung cancer

Dose-escalation study of proton beam therapy with chemotherapy for locally advanced non-small lung cancer - Proton beam therapy dose escalation for NSCLC

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005585

Enrollment

Registered

2011-05-12

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable Non-small Lung Cancer

Interventions

Proton beam therapy 66-74 GyE (Cisplatin 60mg/m2 + TS-1 40mg d1-d4)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically proven Non-small lung cancer, Stage IIIA-IIIB ECOG PS 0-1 Tumor size was measured by 4 wks before registration Good organ function

Exclusion criteria

Exclusion criteria: Drug allergy Active infection Lymph node metastasis at contra-lateral hiller, supraclavicular region. P Severe complication Apparent interstitial pneumonitis

Design outcomes

Primary

Measure	Time frame
To determine maximum torrelated dose and recommended dose	—

Secondary

Measure	Time frame
Adverse event Tumor response survival rate	—

Countries

Japan

Contacts

Public ContactHiroshi Fuji

Shizuoka Cancer Center Division of Proton therapy

h.fuji@scchr.jp055-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026